Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women.

ABSTRACT:

Background

A blood-based assay that could quantify HIV susceptibility would be very valuable for HIV prevention research. Previously, we developed and validated an ex vivo, flow-based, HIV entry assay to assess genital HIV susceptibility in endocervical CD4+ T cells.

Methods

Here we assessed whether this tool could be used to predict HIV risk using blood-derived CD4+ T cells in a rigorously-blinded, nested case-control study using blood samples collected from high-risk, HIV-uninfected South African women enrolled in the CAPRISA 004 clinical trial. Cases, subsequently acquiring HIV were sampled prior to HIV infection and compared with controls, who remained HIV-uninfected. The primary endpoint was ex vivo entry of a CCR5-tropic HIV founder virus into blood CD4+ T cells. Secon

SUBMITTER: Joag V 

PROVIDER: S-EPMC6037376 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature